%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
107 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T11:46:14Z
2024-03-29T03:22:30-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T03:22:30-07:00
application/pdf
Heather
2004-57.jan
uuid:e0bf72b6-1dd1-11b2-0a00-4a0827edca00
uuid:e0bf72b8-1dd1-11b2-0a00-380000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 7 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 9 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 11 0 R/Type/Page>>
endobj
119 0 obj
[124 0 R]
endobj
120 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0183 Tw 10 0 0 10 53.468 529.6616 Tm
(group\); in all this group made up 26% of the whole popula-)Tj
0 Tw 0 -1.2 TD
(tion\). )Tj
/T1_1 1 Tf
-0.0249 Tw 0 -1.44 TD
[(Reasons for tr)37 (eatment discontinuation.)]TJ
/T1_0 1 Tf
15.6665 0 Td
(Inadequate symptom)Tj
0.0293 Tw -15.6665 -1.2 Td
(relief was the main reported reason for treatment discontin-)Tj
0.02499 Tw 0 -1.2 TD
(uation in all drug classes.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(DISCUSSION)Tj
/T1_0 1 Tf
0.11549 Tw 0 -1.2 TD
(The low rate of disease control \(45%\) as assessed subjec-)Tj
0.0287 Tw T*
(tively by patients was corroborated by the finding that 53%)Tj
-0.0278 Tw T*
[(had a BASDAI greater than 40 \(data not shown\). )18 (These poor)]TJ
0.0042 Tw T*
(outcomes were noted despite current use of NSAID by 79%)Tj
0.11411 Tw T*
[(of patients, in keeping with earlier studies in lar)18 (ge patient)]TJ
0 Tw T*
(populations)Tj
0 Tc 7.5 0 0 7.5 100.1306 386.5616 Tm
(12)Tj
-0.00011 Tc -0.01961 Tw 10 0 0 10 107.6306 383.2616 Tm
(, and past or current use of salazopyrine and/or)Tj
0.1134 Tw -5.4163 -1.2 Td
[(MTX by 71% of patients. )18 (Thus, most of the patients with)]TJ
-0.02229 Tw T*
(poor disease control probably received optimal treatment. In)Tj
0.1384 Tw T*
[(keeping with our findings, )18 (W)80 (ard, )]TJ
/T1_1 1 Tf
14.1181 0 Td
(et al)Tj
/T1_0 1 Tf
2.2763 0 Td
(reported a poor 6-)Tj
-0.00211 Tw -16.3944 -1.2 Td
(month continuation rate for a newly started NSAID \(25% to)Tj
0.01221 Tw T*
(54%\), as well as for salazopyrine and MTX \(58% and 61%,)Tj
0 Tw T*
(respectively\))Tj
0 Tc 7.5 0 0 7.5 105.1013 314.5616 Tm
(2)Tj
10 0 0 10 108.8513 311.2616 Tm
(.)Tj
-0.00011 Tc 0.07941 Tw -4.3383 -1.2 Td
(That conventional treatments failed to provide adequate)Tj
-0.0024 Tw -1.2 -1.2 Td
[(symptom relief in over half the patients with SpA)-193 (belonging)]TJ
0.0173 Tw T*
[(to a patient or)18 (ganization is the main finding from our study)65 (.)]TJ
0.1151 Tw T*
(Our recruitment method may have led to selection bias in)Tj
0.13989 Tw T*
(favor of patients with poorly controlled disease since this)Tj
0.0554 Tw T*
[(type of patient may be more likely to join a patient or)18 (gani-)]TJ
0 Tw T*
(zation. )Tj
0.0074 Tc 0.36749 Tw 1.2 -1.2 Td
[(An additional lar)18 (ge-scale study among of)18 (fice-based)]TJ
-0.00011 Tc 0.0448 Tw -1.2 -1.2 Td
(rheumatologists would be useful for determining the extent)Tj
0.03439 Tw T*
(to which our findings can be generalized to the entire spec-)Tj
0.0914 Tw T*
(trum of patients with SpA. It should be noted that 40% of)Tj
-0.01601 Tw T*
(the poorly controlled patients \321 26% of the whole group \321)Tj
-0.01961 Tw T*
[(fulfilled the main requirements of the recent )55 (ASAS response)]TJ
0.0569 Tw T*
(criteria recommendations for the use of anti-TNF agents in)Tj
-0.0002 Tc 0 Tw T*
(AS)Tj
0 Tc 7.5 0 0 7.5 66.2463 134.5616 Tm
(13)Tj
-0.00011 Tc 0.2787 Tw 10 0 0 10 73.7463 131.2616 Tm
[(. )55 (Although our results were obtained in a selected)]TJ
0.2388 Tw -2.0278 -1.2 Td
(patient population, they suggest that many patients with)Tj
0.17799 Tw T*
[(SpA)-373 (may be candidates for biotherapies, should these be)]TJ
0.02499 Tw T*
(found safe for longterm use. )Tj
/T1_2 1 Tf
0 Tw 26.4 43.44 Td
(REFERENCES )Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 324.468 519.6616 Tm
[(1.)-875 (Amor B, Dougados M, Khan MA. Management of refractory )]TJ
1.675 -1.25 Td
(ankylosing spondylitis and related spondyloarthropathies. Rheum)Tj
0 -1.25 TD
[(Dis Clin North )55 (Am 1995;21:1)37 (17-28.)]TJ
-1.675 -1.25 Td
[(2.)-875 (W)80 (ard MM, Kuzis S. Medication toxicity among patients with )]TJ
1.675 -1.25 Td
[(ankylosing spondylitis. )55 (Arthritis Rheum 2002;15:234-41.)]TJ
-1.675 -1.25 Td
[(3.)-875 (W)80 (ard MM. Health-related quality of life in ankylosing spondylitis:)]TJ
1.675 -1.25 Td
[(a survey of 175 patients. )55 (Arthritis Care Res 1999;12:247-55.)]TJ
-1.675 -1.25 Td
[(4.)-875 (Dougados M, Maetzel )55 (A, Mijiyawa M, )55 (Amor B. Evaluation of )]TJ
1.675 -1.25 Td
[(sulphasalazine in the treatment of spondyloarthropathies. )55 (Ann)]TJ
T*
(Rheum Dis 1992;51:955-8.)Tj
-1.675 -1.25 Td
[(5.)-875 (Clegg DO, Reda DJ, )18 (W)80 (eisman MH, et al. Comparison of )]TJ
1.675 -1.25 Td
(sulfasalazine and placebo in the treatment of ankylosing )Tj
T*
[(spondylitis. )55 (A)-220 (Department of )18 (V)111 (eterans )55 (Af)18 (fairs Cooperative Study)65 (.)]TJ
T*
(Arthritis Rheum 1996;39:2004-12.)Tj
-1.675 -1.25 Td
[(6.)-875 (Dougados M, van der Linden S, Leirisalo-Repo M, et al.)]TJ
1.675 -1.25 Td
[(Sulfasalazine in the treatment of spondylarthropathy)65 (. )55 (A)-220 (randomized,)]TJ
T*
[(multicenter)40 (, double-blind, placebo-controlled study)65 (. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38:618-27.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875 (Clegg DO, Reda DJ, )55 (Abdellatif M. Comparison of sulfasalazine and)]TJ
1.675 -1.25 Td
(placebo for the treatment of axial and peripheral articular )Tj
T*
(manifestations of the seronegative spondylarthropathies: a)Tj
T*
[(Department of )18 (V)111 (eterans )55 (Af)18 (fairs cooperative study)65 (. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:2325-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875 (V)111 (an Den Bosch F)80 (, Kruithof E, Baeten D, et al. Randomised )]TJ
1.675 -1.25 Td
(double-blind comparison of chimeric monoclonal antibody to tumor)Tj
T*
(necrosis factor alpha \(infliximab\) versus placebo in active )Tj
T*
[(spondylarthropathy)65 (. )55 (Arthritis Rheum 2002;46:755-65.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Braun J, Brandt J, Zink )55 (A, et al. )18 (T)35 (reatment of active ankylosing)]TJ
1.675 -1.25 Td
(spondylitis with infliximab: a randomised controlled multicentre)Tj
T*
[(trial. Lancet 2002;359:1)37 (187-93.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Gorman J, Sack K, Davis JC. )18 (T)35 (reatment of ankylosing spondylitis)]TJ
2.175 -1.25 Td
(by inhibition of tumor necrosis factor \(alpha\). N Engl J Med)Tj
0 Tc 0 Tw T*
(2002;346:1349-56.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (Mease PJ, Gof)18 (fe BS, Metz J, )18 (V)111 (an der Stoep )55 (A, Finck B, Bur)18 (ge DJ.)]TJ
2.1381 -1.25 Td
(Etanercept in the treatment of psoriatic arthritis and psoriasis: a)Tj
T*
(randomised trial. Lancet 2000;356:385-90.)Tj
-2.175 -1.25 Td
[(12.)-875 (Calin )55 (A, Elswood J. )55 (A)-220 (prospective nationwide cross-sectional study)]TJ
2.175 -1.25 Td
(of NSAID usage in 1331 patients with ankylosing spondylitis. )Tj
T*
(J Rheumatol 1990;17:801-3.)Tj
-2.175 -1.25 Td
[(13.)-875 (Braun J, Pham )18 (T)74 (, Sieper J, et al. International )55 (ASAS consensus)]TJ
2.175 -1.25 Td
(statement for the use of anti-tumour necrosis factor agents in)Tj
T*
[(patients with ankylosing spondylitis. )55 (Ann Rheum Dis )]TJ
0 Tc 0 Tw T*
(2003;62:817-24.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 549.468 56.4344 Tm
(79)Tj
ET
0 0 0 0 k
53.532 70.203 203 -16.865 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.0723 Tm
[(Oniankitan, et al: Contr)37 (ol of SpA)]TJ
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc -0.02299 Tw 8 0 0 8 126.532 737.0293 Tm
[(T)92 (able 3. )]TJ
/T1_0 1 Tf
-0.00011 Tc 3.6169 0 Td
(Current symptoms and disease activity indices in the patients with well-\
controlled and poorly controlled)Tj
0.02499 Tw -3.6169 -1.25 Td
[(disease, based upon current treatment. Data are presented as n \(%\) or \
mean \(\261)-260 (SD\).)]TJ
15.6155 -2.5 Td
[(Overall)-4525 (Good Disease)-2307 (Poor Disease)]TJ
0 Tc -0.058 -1.25 Td
[(n = 507)-4048 (Control n = 230)-1302 (Control n = 277)-3283 (p)]TJ
-15.5575 -2.5 Td
[(BASDAI)-11469 (40 \261)-260 (19.1)-4604 (29.6 \261)-260 (19.2)-3148 (54.2 \261)-260 (19.3)-3081 (0.0001)]TJ
T*
[(BASFI)-12357 (28 \261)-260 (20.2)-4604 (18.8 \261)-260 (19.1)-3148 (38.0 \261)-260 (23.1)-3081 (0.0001)]TJ
-0.00011 Tc T*
[(Morning stif)18 (fness duration, min)-2039 (48.8 \261)-260 (47.5)-4979 (37 \261)-260 (41)-4648 (58 \261)-260 (50)-3831 (0.0001)]TJ
T*
(Current axial symptoms)Tj
1.171 -1.25 Td
[(Thoracolumbar spine)-5299 (349 \(68.8\))-4637 (109 \(47.4\))-3556 (240 \(86.6\))-3286 (0.0001)]TJ
T*
[(Cervical spine)-8076 (238 \(46.9\))-4887 (66 \(28.7\))-3806 (172 \(62.1\))-3286 (0.0001)]TJ
T*
[(Sacroiliac joints)-7353 (192 \(37.9\))-4887 (48 \(20.9\))-4181 (144 \(52\))-3661 (0.0001)]TJ
-1.171 -1.25 Td
[(Current peripheral arthritis)-4253 (134 \(26.4\))-4887 (39 \(17.0\))-4056 (95 \(34.3\))-3536 (0.0001)]TJ
0 Tw T*
(Enthesopathy)Tj
0.02499 Tw 1.171 -1.25 Td
[(Heel pain)-9964 (140 \(27.6\))-4887 (36 \(15.7\))-3806 (104 \(37.5\))-3286 (0.0001)]TJ
0.1243 Tw -1.171 -2.5 Td
(BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath \
ankylosing spondylitis functional)Tj
0 Tw T*
(index.)Tj
ET
126.532 720.5 m
485.5 720.5 l
127.5 691.5 m
485.5 691.5 l
126.532 581.5 m
486.532 581.5 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_3 8 Tf
106.328 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
8;Z\7$$*pK#ikq,j?$(G,IBDLRrkN;RO3#d/IMlk=S7ON)"NR9qsfjD%t8X"*@otg
F0,,Ao;gMf#@7Ir[,R4lI7"uPQ$M7P40X1!5D7X%DHle6QIqn%CCjhh^:N5S?79ps
(;T,iMC#3S]0W6-?@Sr&Q!^ZF2-s1rmEiS1.>bIU_qe15Prm]QT&%F$D8OnsZh@R0l5(;SpippF5q@bGHkalTJJ>Wgnj
jK2\W5gfXe[$NPo]O!Ze0JV;1mJ2`JHUE1uB=R9oaJ=G%P#(
6N]3lQgQ"#[#[`m_\/t$j+H1TEfT*,BiM23L8G$K_0hhaBe'tHBGaWb6JUuRjW;h+
7KFTZ#b]"*)l1`"cM@Z%AHgVj&:G7^R9;Ke1'\;TH9lRQ0O(KO33G:RUEdeK4Q
\!3_9@U
endstream
endobj
15 0 obj
[/Indexed/DeviceRGB 255 14 0 R]
endobj
14 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
37 0 obj
<>
endobj
39 0 obj
<>
endobj
57 0 obj
<>
endobj
78 0 obj
<>
endobj
113 0 obj
<>
endobj
55 0 obj
<>
endobj
70 0 obj
<>stream
HLPw9v_lEY=I1s_U% B0J Gpܝ{8,h=NJ1
"5*`t1X'TMZC<7cw%8;>yKaIQk^^hMs
xHHy~29SQ]tD4GOEIF1,6V9U2ᅂaIRb܋ZMx\dR[-*W%d!,!fr.!Ⲉc%2\h)5%HȲeUN`zUe-E]'LC:b'a&ɹd=}ؖnt]:%\*շNo+}
.6͟KnAc14XRc5W-6?d[[䠜n)MuoWys߁Rz2 rSʼn)+'|Ѹc,<
?e'9 v8iw+~saf_]UIua?19)
M@ XXl44sHDl6*gq
'{HFHiV4ozߨO@FA%w-1[p`Cn͗JQBJ֢bk<ԢY|'FW-jtavp~^Pp `||gPz 0B
ִwDfyj<3ܟ@JWG2NTHTuJd{a`\]
ΫD\=P&oE=_)y6o[ -j"o./$HTLK
q
pJD}C?[+jBW)GgJT4'EW˛yن^DÜRd(_Gzc|^=ʃ_r6ؠ^oDxsȆ76
jj`CnGJ %6Vu\eeK A0t!(?z:[@W(K
ȫ9P)ѩM'YyA 1ny]4uLEmܧKDtZ_#_9o/`Ȏ2c>>$O*N8z8;oC)X
sqbB0O,"8sGZրV
t=/.y?35Çȡxen
\ܔ"}cCוWv##Y.x3'dw%j z8(-E2Fsc 9br}Gr]̬A%outkCcۑA뿌5C<5>:^='Fm/Q/
t~ɐ
dw,C>Gp>M ˦6D:P˟m]AzR>S)[fk6/L?UK2;e.z: ,0Y|\3`}x#?0&6qza% LÑBAT"7["^v5ܑ̺UU<Szh R/kp
endstream
endobj
44 0 obj
<>
endobj
73 0 obj
<>stream
HUiPTW~~({!?=%X7p@yFb8
>o-L.xȲhh7E:mw{
aw!=:)'J0 5rh$QMJ?ΕfK= rn!avLXrf^Lhv~qYZ('ͫ8O6UdpxFHpm0<#ڡQ+[?.N?{wwwD\,'p6Jdqe 륔Oͤ8}}/r$Fj3
'aFbSɹ@Y:4NEv549ڛJ;I^Aɹնx+ؽOLt(-qc3{)$ ŗB(k;]捋od(M]u
4\FN!;h=-1:{vzN̔SvgPٵ+tϾݍ26~xk n$eœ!s5ϠQ-Ԃ˷WF2WGľo!Хh=oH7ɯ6ֆ 恜(49ңGk{(ye
a :CtI@7?*"5
~Ok)B9KYc`ack
V
qXލZ#ayuRRT"LdxhFԢ[y=ꑆ4T<.+g'J2++=N?D!ʀ-!nPs[sYV}މ[VB[ uDIꟑPȢFN)J HWJ>FwGU#-s~D"*UBQfq62m{YgmkkZEO[#%rluzn iFȽ:Q^s-W=quGn)'QciC,ۋa ]:Y͗o2|YEPY/:1